ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma ("R/R B-NHL") -April 09, 2024 at 05:30 pm EDT
– Twenty patients with indolent and aggressive R/R B-NHL received evorpacept plus standard rituximab and lenalidomide – Evorpacept plus R2 was well tolerated with a safety profile similar to...
United States Sophia Randolph Caitlyn Doherty Development Pillars American Cancer Society American Association For Cancer Research
Source: marketscreener.com